

Feasibility of a physiotherapy-based Godelive Denys-Struyf (GDS) muscle and articulation chain treatment for patients with chronic low back pain and lumbar disc degeneration: a pilot randomised controlled trial

Margreth Grotle (✉ mgrotle@oslomet.no)

Oslo Metropolitan University: OsloMet - storbyuniversitetet <https://orcid.org/0000-0001-8243-1143>

Sidsel Lombardo

Vestfold Hospital Trust: Sykehuset i Vestfold HF

Milada Cvancarova Småstuen

Oslo Metropolitan University: OsloMet - storbyuniversitetet

Gunvor Hilde

Oslo Metropolitan University: OsloMet - storbyuniversitetet

Research

Keywords: Pilot randomised controlled trial, Lumbar disc degeneration, GDS muscle and articulation chain treatment, Exercise, Rehabilitation

Posted Date: May 12th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1536043/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Feasibility of a physiotherapy-based Godelive Denys-Struyf**
2 **(GDS) muscle and articulation chain treatment for patients**
3 **with chronic low back pain and lumbar disc degeneration: a**
4 **pilot randomised controlled trial**

5
6 Sidsel Lombardo^a, Gunvor Hilde^b, Milada Cvancarova Småstuen^b, Margreth Grotle^{b, c, *}

7 ^a Physiotherapy Department at Vestfold Hospital Trust (VHT), P.O.Box 2168, 3103 Tønsberg,
8 Norway,

9 ^b Oslo Metropolitan University, Department of physiotherapy, P.O. Box 4 St. Olavs plass, NO-
10 0130 Oslo, Norway

11 ^c FORMI, Oslo University Hospital HF, Ulleval, Bygg 37b, P.O. Box 4956, Nydalen, 0424, Oslo,
12 Norway

13
14 * Corresponding author. Tel +47 90111172, e-mail address: mgrotle@oslomet.no

15
16 Other e-mail addresses: sidsel.lombardo@siv.no (S. Lombardo), ghilde@oslomet.no
17 (G.Hilde), milasm@oslomet.no (M.C. Småstuen)

22 **Abstract**

23 Background

24 Patients with chronic low back pain (LBP) and lumbar disc degeneration are recommended
25 to try out non-surgical treatment options before surgery. There is need for good non-surgical
26 alternatives that can be adapted to the patient's needs and level of function. The aim of this
27 pilot trial was to test study feasibility of a future full randomized controlled trial (RCT)
28 evaluating the feasibility and benefit of the physiotherapy-based Godelieve Denys Struyf
29 (GDS) muscle and articulation chain treatment for patients referred to surgical assessment in
30 a hospital outpatient clinic.

31 Methods

32 This study is a single-centre, two-arm pilot RCT conducted in a regional hospital in Norway.
33 Patients of age 35-75 years with chronic (> 3 months) LBP and degenerative lumbar disc(s)
34 verified by imaging, were included. They filled in a baseline questionnaire prior to
35 randomization, including the Oswestry Disability Index (ODI), numerical rating scale for pain
36 in back and pain in leg, and the EuroQoL 5L. Patients in the control group were free to use
37 treatment as usual. Patients in the intervention group received 8 sessions of GDS muscle and
38 articulation chain treatment.

39 Results

40 The recruitment rate was slow, half of the referred patients met the inclusion criteria, but
41 majority of eligible participants (94%) were willing to participate. A total of 30 patients were
42 randomized into the two groups. The randomization led to skewed distribution of radiating
43 leg pain in the two groups. All participants except one (97%) completed four months follow-
44 up. No serious adverse events attributable to the trial treatments were reported. The

45 Oswestry Disability Index (ODI) and leg pain intensity scale were both suitable as primary
46 outcomes in a full trial. The mean change in the ODI score was 8.7 (SD 16.1) points in the
47 GDS arm whereas there was a minor deterioration in the ODI scores of -3.7 (7.5) points in
48 the control arm. A sample size calculation based on the ODI scores resulted in a Number
49 Needed to Treat of 3.

50 Conclusions

51 A future full RCT is feasible and would provide evidence about the effectiveness of a GDS
52 treatment for patients with chronic LBP with degenerative disc degeneration.

53 Trial registration

54 Clinical trials.gov ID: 910193

55

56 Keywords

57 Pilot randomised controlled trial; Lumbar disc degeneration; GDS muscle and articulation
58 chain treatment; Exercise; Rehabilitation;

59

60 Key messages regarding feasibility

61 **1) What uncertainties existed regarding the feasibility?** The most important uncertainty is
62 the duration of recruitment of patients to a full-scale trial.

63 **2) What are the key feasibility findings?** This pilot trial showed that feasibility worked well
64 in terms of eligibility criteria, patient information, processes for consent and randomization,
65 follow-up rate, treatment outcomes, treatment protocol, and compliance to the GDS
66 intervention. The recruitment rate was slow, however.

67 **3) What are the implications of the feasibility findings for the design of the main study?** In
68 a future trial it is important to get a more efficient recruitment in place and to stratify for
69 radiating pain to buttock and/or leg.

70

71 **Background**

72 Chronic low back pain and intervertebral disc degeneration

73 Chronic low back pain (LBP) is characterized by persistent and/or recurring pain in the back
74 and is often associated with neurological symptoms in the lower limbs [1]. In ageing people,
75 degenerative changes in the intervertebral disc, such as spinal stenosis with or without
76 degenerative spondylolisthesis, is commonly observed by imaging techniques with
77 prevalence estimates as high as 57% (95% CI 55-60) in patients with LBP [1, 2]. An increasing
78 amount of patients with chronic LBP and intervertebral disc degeneration are referred for
79 surgical treatment, which may take the form of either fusion or decompression of nerve
80 roots [3]. Surgery always comes with higher costs and greater risks of adverse events as
81 compared to conservative treatment options such as multidisciplinary rehabilitation, which
82 has shown similar effectiveness as surgical treatments [4, 5]. In cases with spinal stenosis,
83 the effectiveness of surgery versus conservative treatments might be better, but the
84 evidence is insufficient [6, 7]. Conservative treatment modalities are often recommended as
85 first-line treatments, and these typically are graded activity or exercise programs that target
86 improvements in daily functions taking individual needs, preferences, and capabilities into
87 account [3]. For patients who do not respond to first-line treatments and who are
88 substantially disabled by pain, an active approach might be combined with cognitive

89 behavioral therapy [7, 8, 9] and passive modalities such as spinal mobilization, massage, or
90 acupuncture [10].

91

92 Motor control exercises as treatment modality for chronic low back pain have gained
93 popularity in physiotherapy practice, which is based on several randomized, controlled trials
94 during the last two decades showing promising effect when treating patients with chronic
95 low back pain [11, 12]. Motor control exercises focuses on the activation of the deep trunk
96 muscles and targets the restoration of activation and co-ordination of these muscles. In a
97 systematic review from 2016 there was low to moderate quality evidence that motor control
98 exercises have a clinical effect for improving pain and disability at short, intermediate and
99 long-term follow-up when compared with a minimal intervention for patients with chronic
100 low back pain [13]. However, this systematic review also concludes that motor control
101 exercises are not superior to other forms of exercises. Therefore, they recommend that the
102 choice of exercise for chronic low back pain should depend on patient or therapist
103 preferences.

104

105 Motor control exercise methods are numerous and might vary slightly across nations. One
106 frequently used method in France, Belgium, and Mediterranean countries is named the
107 Godelieve Denys-Struyf (GDS) muscle and articulation chain method. It was developed in the
108 seventies by the Belgian physiotherapist Godelieve Denys-Struyf. It has since then been
109 further developed in Belgium and France, with the French physiotherapist Philippe
110 Campignon as a main contributor and author. The GDS method classifies all muscles,
111 including those influencing lumbar-pelvic and spinal stability, into six muscle chain groups,
112 according to their anatomy and role in postures and movements. It builds on the assumption

113 that balanced tension and activation across these muscle chains contributes to adequate
114 neuromuscular, biomechanical and psychomotor control, whereas unbalanced tension
115 across them may explain the presence of pain, as subacute or chronic low back pain LBP. The
116 aim of GDS treatment is to obtain balance between tonus/activity in the different muscle
117 chains and reprogram certain movements in order to achieve optimal motor control. To our
118 knowledge, two former randomized controlled studies have evaluated the effect of GDS
119 treatment for LBP [14, 15]. Diaz-Arribas et al from 2009 compared 15 GDS sessions to 15
120 sessions of conventional physiotherapy among 137 patients with non-specific chronic low
121 back pain searching primary care. After 3 and 6 months, the GDS intervention group showed
122 significantly larger improvements in pain, function and quality of life as compared to the
123 control group [14]. A cluster randomized trial from 2015 included 461 patients with
124 subacute or chronic LBP [15]. They received either GDS sessions by group or individually, or
125 control treatment (as usual). The results showed that GDS provided in group sessions
126 improved function significantly more than the two other groups, but the effect was small.
127 There has been no publication about GDS treatment for patients with chronic LBP with
128 additional verified intervertebral disc degeneration.

129
130 The aim of this paper is therefore to report a pilot randomized controlled trial (RCT) to test
131 the feasibility of a future, full-scale trial to evaluate the effectiveness of a GDS treatment as
132 compared to treatment as usual for patients referred to a surgical assessment by an
133 orthopaedic specialist. The specific objectives were to evaluate feasibility in terms of a)
134 process of recruitment, including willingness of participants to be randomized; b) selection
135 criteria for a full-scale trial process of recruitment, the randomization procedure, and follow-
136 up rates; c) participants experience of and compliance to GDS treatment; and d) outcome

137 measures, including estimate the variability of outcomes in this patient population and
138 calculate sample size for a full-scale trial.

139

140 **Methods**

141 This pilot randomized controlled trial is reported in line with the CONSORT 2010 extended
142 guidelines to randomized pilot and feasibility trials [\[16\]](#).

143

144 Trial design and setting

145 This pilot trial was a single-centre, two-arm, assessor-blinded pilot RCT with a treatment
146 phase of 10 to 12 weeks (4 weekly sessions, then some more spaced) and follow-up around
147 4 months after inclusion. The trial was performed in accordance with the Helsinki
148 Declaration and the International Conference on Harmonisation of Good Clinical Practice,
149 and was registered at ClinicalTrials.gov in June 2020 under the identifier: NCT910193. The
150 Regional Committee for Medical Research Ethics South-East Norway (2017/2547/REK sør-
151 øst) approved the pilot trial before it started. The study was conducted at the Department of
152 Physiotherapy, Vestfold Hospital Trust (VHT) Norway, and was funded by the Hospital.
153 Researchers at the Department of Physiotherapy, Oslo Metropolitan University, were
154 responsible for design, allocation procedure and methods for this pilot trial. All participants
155 gave written informed consent before entering the study.

156

157 Participants

158 The participants were included according to the following criteria: (i) Age 35-75 years, (ii)
159 Willing and able to participate, (iii) Chronic (> 3 months) low back pain, and (iv) Degenerative

160 disc(s) in the lumbar spine verified by imaging (2022 ICD-10-CM Diagnosis Code M51.36).
161 Participants were excluded according to the following criteria: (i) Severe psychiatric disorder,
162 (ii) Comorbidity that prevented the patient from performing exercises and gradually increase
163 general activity when back / leg function allowed it, (iii) Undergone spinal fusion or referred
164 to spinal surgery, (iv) Pregnancy, and (v) In a process of applying for disability benefits /
165 compensation due to back pain.

166

167 Identification and recruitment

168 The study participants were referred from General Practitioners (GPs) in Vestfold county to a
169 specialist in orthopaedic surgery or specialists in physical medicine at VHT for an
170 examination and assessment with respect to surgical treatment or not. If the referred
171 patients were considered inoperable or wanted to postpone surgery, they were referred
172 further to the project staff at the Department of Physiotherapy at VHT, where they were
173 informed about the study and screened for eligibility criteria. Participants who were willing
174 to participate received a full participant information sheet and consent form. After filling in
175 the baseline questionnaire the participants were sent home and informed that they would
176 be contacted regarding the treatment allocation within the next day. The participants had
177 the opportunity to withdraw at any time, without any consequence for the person's further
178 health services or opportunity for ordinary treatment.

179

180 Randomisation

181 Eligible participants who gave written informed consent to participate were randomised in a
182 1:1 ratio. A statistician (MZS) at the Musculoskeletal Health Research Group

183 (MUSKHealth.com) at OsloMet was responsible for the randomization sequence. A
184 collaborator in the project staff (SS) contacted (by telephone text message) the statistician at
185 OsloMet for the allocation code, and directly informed the participant about their allocated
186 treatment.

187

188 Blinding

189 In this study, we could not blind the participants with respect to what treatment they got,
190 nor the treating physiotherapist (SL). However, the project collaborator (SS) who
191 administered the information regarding treatment allocation and the post-treatment
192 questionnaire after 4 months, was blinded with respect to treatment allocation. In addition,
193 analyses of patient-reported outcomes were conducted and verified by the blinded
194 statistician.

195

196 Sample size

197 This pilot study aimed to explore the methods proposed to conduct a full-scale trial and not
198 to detect a true difference between treatment groups. In this context we relied on a
199 recommendation of at least 12 participants per group as a rule of thumb for pilot studies²⁵.
200 Taking into account potential drop-out of participants we decided to include 30 participants
201 for this pilot study. As an external pilot trial interim analyses and stopping rules were not
202 required.

203

204 Interventions

205 The participants in the intervention group were examined and treated according to the
206 principles of the GDS method. We aimed to understand the patient's nature and muscular
207 patterns, unravel tensions that hinder natural body movement in order to stimulate more
208 functional movement patterns for ergonomic body use. Together with the patient we
209 proposed a treatment program. In line with the GDS method, we applied techniques such as
210 various stretching and respiration exercises, massages, mild manipulations and movements
211 for good function, all adapted to each patient's characteristics and needs. The patient was
212 also encouraged to increase their body awareness, and to perform tailored home exercises
213 that should typically be effectuated for 15 to 20 minutes once or twice a week. They
214 received up to 8 individual treatment sessions enduring approximately 1 hour, including the
215 baseline examination. The patients paid a minor fee for the treatments, 50% of the normal
216 physiotherapy rate in terms of price.

217 The control group received standard treatment from their GP, possibly referred to
218 physiotherapy, chiropractor or whatever they preferred. Type of treatment received in the
219 follow-up period was recorded in the follow-up questionnaire.

220

221 Data collection

222 Baseline data collection consisted of a baseline questionnaire, which was administered prior
223 to randomization. Patient-reported outcomes were assessed approximately 4 months after
224 treatment allocation and were sent to patients per mail with a stamped envelope for return.

225 Patients who did not respond were reminded twice. All data collected on paper was
226 transferred to an Epi-Data program at VHT

227

228 The baseline questionnaire consisted of information regarding sociodemographic
229 background variables and standardized outcome measures. Background variables concerned
230 age, gender, level of education (primary and high school, college or university < 4 years, or
231 university education of 4 years or more), smoking (yes/no), marital status (married, co-
232 habitant, single), employment status (employed, sick leave, disability pension, age
233 pensioned, unemployed), pain localization (back pain, radiating pain to buttocks and/or
234 legs), sensibility changes in back/buttocks/legs), former surgery (yes/no/fixation?), pain
235 duration (< 3 months, 3-12 months, 12-24 months, > 2 years), and use of pain or
236 sleep/relaxation medication weekly or more (yes/no). In order to describe the patients risk
237 of persistent disabling pain, the STarT Back screening questionnaire was used [17].

238

239 Four patient-reported outcome measures were included. The primary outcome, functional
240 disability due to low back pain was assessed by using the Oswestry Disability Index (ODI) [18,
241 19], version 2.0. This questionnaire assesses has ten different sections. The first section
242 assess pain intensity and the following nine sections assess how back or leg pain is affecting
243 the patient ability to manage activities of daily living. The score for each section is rated from
244 0 to 5 and the highest possible score for all sections is 50. The patient's score is then
245 transferred into a percentage score ranging from 0 (no) to 100 % (maximum pain-related
246 disability). Secondary outcomes were pain intensity, respectively in back and leg, assessed
247 on a visual analogue scale ranging from 0 to 100 [20], and health-related quality of life
248 measured by the EuroQoL 5L (EQ-5D-5L) [21].

249

250 For each participant, the treating physiotherapist recorded full details of the treatment
251 period, such number of treatment sessions, any non-attendance, and any adverse events.

252 We did not expect serious adverse events in relation to the treatment, except minor
253 soreness in the muscles after the initial sessions. At follow-up, treatment satisfaction was
254 measured by one question with a 5-point ordinal response scale ranging from “very
255 satisfied” to “very dissatisfied”. Use of other healthcare modalities were also assessed by
256 self-report at the follow-up; frequency and type of health care provider was included here
257 (none, general practitioner, specialist, chiropractor, physiotherapist, manual therapist, other
258 providers).

259

260 Statistical analysis

261 As a pilot trial, the analysis was mainly descriptive to inform the design of a full trial. A
262 CONSORT flowchart shows the flow of participants into the pilot trial, numbers allocated to
263 each treatment arm, numbers of follow-up responders, and number of participants included
264 in the analysis. Feasibility in terms of selection criteria, recruitment and follow-up rates,
265 adherence to and experiences by the GDS treatment are presented descriptively. Descriptive
266 statistics were used to summarise background and clinical variables at baseline, which are
267 presented for the two treatment arms. Descriptive statistics were also used to summarise
268 the four key clinical outcomes for each treatment arm: continuous variables are presented
269 with mean and standard deviation (SD) and median and interquartile range (IQR) due to the
270 small sample size. Categorical variables are presented as proportions and percentages. The
271 degree of missing data to the four outcome measures is also reported. The distribution of
272 baseline and follow-up scores of the four outcome measures were visually inspected by
273 distribution plots. The mean change in outcome scores from baseline to four months was
274 calculated for each treatment arm along with associated 95% confidence intervals (CI).
275 When normally distributed, the mean difference between the two treatment arms for the

276 four outcome measures were analyzed by analysis of covariance (ANCOVA), adjusting for the
277 baseline scores in the outcome measures. The mean difference between the two treatment
278 arms and the associated 95% CI in the four outcome measures were used to inform the
279 optimal choice of a primary outcome for a full trial. This also included the amount of missing
280 data at the item and scale levels, any evidence of floor or ceiling effects, the precision of the
281 outcome measures based on the standard error of measurement and their responsiveness
282 to change.

283

284 In order to calculate Number Needed to Treat (NNT) for sample size calculations for a future
285 full-scale trial, the proportions of participants achieving a *minimal important change (MIC) in*
286 *disability* was calculated for the ODI. The MIC for the ODI is estimated to be a change of 8 to
287 10 points on the 0-100 scale for Norwegian patients undergoing surgery due to spinal
288 stenosis [22] or disc herniation [23]. By dichotomizing the ODI change score to 8 or more
289 versus less than 8, we calculated the NNT by estimating the Absolute Risk Reduction (ARR) in
290 the intervention versus the control group and dividing 1 by this estimate (NNT= 1/ARR) [24,
291 25]. SPSS windows was used in the statistical analyses.

292

293 Results

294 Process of recruitment, eligibility, and willingness to participate

295 During a period of 19 months (from 15.11.2018 to 03.07.2020) a total of 316 patients with
296 chronic LBP were referred to and consulted an orthopaedic surgeon or physical medicine
297 doctor at Vestfold hospital (estimated numbers from the hospital administration). Most of
298 them, 253 patients, were further referred to surgery, leaving 63 eligible participants for the

299 current pilot project. Of the 63 eligible participants, 35 participants were referred further to
300 the physiotherapy department for information and possible inclusion, and 30 of these were
301 willing to participate and be randomized into one of the two treatment arms (Fig.1.). The last
302 follow-up in this trial was performed 4 months after randomisation. All patients completed
303 the follow-up, except for one patient in the control arm (reason was not provided) (Fig.1).

304

305 Selection criteria for a full-scale trial

306 The mean age at baseline of the included patients was 58 years (SD 9.7) and 50% were male.
307 Most of the participants had lower levels of education (80%), did not smoke (86%), were
308 married (77%), and 37% were not working. Most of the patients had a verified diagnosis of
309 spinal stenosis without spondylolisthesis, whereas between approximately 16% had spinal
310 stenosis with degenerative spondylolisthesis. Further, 40% of the patients reported the
311 actual pain episode enduring more than two years and 54% used pain medication weekly or
312 more frequently. Only a minor proportion reported use of sleep/relaxation medication
313 weekly or more often (13%) and had a high risk for persistent disabling pain according to the
314 STaRt Screening tool (17%). Table 1 shows baseline characteristics of participants allocated
315 to the intervention- and control group. The randomization led to equal groups with respect
316 to most of the baseline variables except for radiating pain to the buttocks and/or thighs and
317 use of pain medication. A higher proportion of patients reported radiating pain to the
318 buttocks and/or legs in the intervention group as in the control group (60% vs 27%), and
319 more patients in the control group used pain medication. Likewise, the patients in the GDS
320 arm reported a higher baseline score in leg pain as compared to the control arm, with a
321 mean score of 69 versus 49 respectively (or a median score of 70 vs 20) (see Table 2). The

322 scores in back-related disability by the ODI, in back pain, and health-related quality-of-life
323 were similar across the two arms (Table 2).

324

325 Participants compliance to and experience with GDS treatment

326 All participants received the intended treatment based on the allocation. In the GDS arm, 14
327 patients received 8 treatment sessions and one patient had 7 sessions (Fig.1.). The
328 participants complied to the principles in the GDS treatment. Most of them, 11 (73%)
329 reported to be very satisfied with the treatment, and 4 were slightly satisfied. No adverse
330 events or poor experiences were reported, and no unintended consequences were
331 revealed.

332

333 Use of treatment modalities in the control group

334 In the control arm two patients consulted a general practitioner (GP), two received
335 physiotherapy, one chiropractic treatment, one alternative treatment (reflexology), and 9
336 participants reported no treatment during the follow-up.

337

338 Clinical outcome measures and scores

339 There were no missing data for the outcome measures at baseline and follow-up. No floor or
340 ceiling effects were shown in the total score of either ODI or the EQ5D-5L. There were large
341 improvements in mean change scores in both the ODI and in pain intensity in back and leg
342 pain (Table 2), whereas there was a deterioration in these scores in the control arm. There
343 were minor changes in the EQ5D scores in both treatment arms (Table 2). The mean
344 difference estimates, adjusting for the baseline scores of the outcome measure, were

345 significantly larger (both statistically and clinically) in the GDS arm compared to the control
346 arm with treatment as usual, suggesting the effects are of clinical interest and worthwhile to
347 pursue in a future full-scale trial (Table 2).

348

349 Numbers Needed to Treat

350 Achievement of a MIC, based on recommended cut-off value of 8 points in the ODI occurred
351 in 7 out of 15 patients (47%) in the GDS group, whereas in the control group, none of the
352 patients achieved this amount of improvement. This gives a number needed to treat (NNN)
353 of 3.14 meaning that we need to treat three patients with GDS treatment in order to achieve
354 a MIC, in this case a 8 points reduction to the ODI score. Bender's 95% confidence interval
355 around this estimate was wide however (due to small sample size), ranging from 1.90 to
356 18.82.

357

358 Discussion

359 This pilot trial showed that the feasibility in terms of eligibility criteria, patient information,
360 processes for consent and randomization, follow-up rate (short term), treatment outcomes,
361 treatment protocol, and compliance to the GDS intervention worked well. The recruitment
362 rate was slow, however. Furthermore, there was a substantial improvement in back-related
363 disability and pain in the GDS treatment group, whereas there was a minor deterioration in
364 the control group. These differences are interesting and would be worthwhile testing out in
365 a full-scale trial.

366

367 There are however minor adjustments for a full-scale trial to consider. First, the recruitment
368 procedure took longer time than expected. The main reason was probably that the doctors
369 often forgot to send eligible patients to the physiotherapy department and needed frequent
370 reminders of our study. Given that the vast majority of referred eligible participants were
371 willing to participate, and willing to be allocated either to the GDS intervention or control
372 intervention by chance it is possible to conduct a more rapid recruitment. This can be done
373 by inviting all patients referred to an orthopaedic examination with chronic LBP and lumbar
374 disc degeneration to meet with a physiotherapist in the project group, regardless of planning
375 surgery or not. Taking into consideration the costs and the risk of adverse events in surgery
376 these patients could be recommended to try GDS treatment before moving on with surgery.
377 The GDS treatment is considered safe [14, 15] and no adverse events were reported in our
378 study. In contrary, the patients reported to be highly content with this treatment and
379 achieved a substantial improvement in three out of four outcome measures as compared to
380 the participants receiving treatment as usual.

381

382 Another adjustment for a full-scale trial concerns the difference in leg pain between the two
383 groups in this pilot trial. People with LBP and radicular pain or radiculopathy are often more
384 severely affected and have poorer treatment outcomes as compared to those with back pain
385 only [26]. Therefore, in a full-scale trial one should consider a stratified randomization
386 procedure, which will ensure equal distribution of patients with leg pain in the two arms.

387 We believe that the number of GDS treatment sessions was optimal even though some
388 patients would have preferred even more treatments. The participants were encouraged to
389 follow a few principles of movement and to conduct some stretching exercises at home,
390 twice a week or when they felt that their body needed it. On the other hand, a one-hour

391 session of individual GDS treatment is longer than most other physiotherapy sessions. An
392 advantage by this long session is that it gave an opportunity to have a thorough dialogue
393 with the participants, where they often opened up regarding different topics, e.g. previous
394 treatment experiences, how they felt to be constantly searching for effective treatment, and
395 the fear of becoming more disabled than in the current situation. An one-hour session also
396 gave the physiotherapist the opportunity to explore which type of movements the
397 participants tolerated and to adjust treatment and dosage according to the response from
398 the participants.

399

400 The large difference in back-related disability and pain intensity scores after treatment in the
401 GDS group as compared to the control group must be interpreted carefully, as most of the
402 patients in the control group did not seek any treatment during the four months after
403 randomization. Therefore, in a full-scale trial the optimal design would be to include a
404 placebo group in addition to a treatment as usual and GDS group.

405

406 Although it is beyond the scope of any pilot study to claim findings that are generalisable, it
407 is interesting to compare the differences between the two groups in post-treatment scores
408 for the ODI and pain scales from the present pilot trial to findings from other relevant full-
409 scale trials. A mean difference of 13 ODI points (on a 0-100 scale) is a considerable larger
410 mean difference than what was reported in the two previous trials comparing the
411 effectiveness of routine physical therapy and GDS treatment provided for people with
412 subacute and chronic LBP [[14, 15](#)]. A mean difference of 13 ODI points is also larger than in
413 several other trials, which have evaluated the effectiveness of other types of motor control
414 exercises for chronic non-specific LBP on disability [[11, 12, 13](#)]. In a previous Norwegian trial

415 on patients with severe lumbar disc degeneration, in which disc replacement surgery was
416 compared against multidisciplinary rehabilitation, they reported a mean difference of 8.9
417 ODI points (95% CI 4.8 to 13.0) at 12 months and 6.9 ODI points (2.2 to 11.6) at 24 months in
418 favour of disc replacement [27]. It should be noted though that the 95% CI around our 13
419 ODI points mean difference was wider than the 95% CI in the disc replacement trial [27].
420 The wide confidence intervals around our NNN estimate needs to be considered in a sample
421 size calculation for a future full-scale trial.

422

423 Considerations and limitations

424 The main strength of this study is that we adhered to the CONSORT 2010 extended
425 guidelines to randomized pilot and feasibility trials [16]. The findings suggest that in a future
426 full trial one needs to make adjustments concerning recruitment strategy and using a
427 stratified design in order to ensure equal groups. Also, when calculating sample size based
428 on our pilot results, the wide confidence intervals around the NNN estimate should be
429 acknowledged and as well as taking into account a higher rate of drop-out of patients
430 followed over a longer period in a future full scale RCT. The main limitation is the lack of
431 insight in the process around referring potential participants after the initial clinical
432 consultation with a specialist at the hospital, and a short follow up period (4 months after
433 treatment allocation).

434

435 Conclusion

436 This pilot trial showed that a future full-scale trial for evaluating the effectiveness of GDS
437 treatment for patients with chronic LBP and intervertebral disc herniation is feasible. Amendments

438 for a future trial is to get a more efficient recruitment in place ensuring access to all eligible
439 participant, and also stratify for radiating pain to buttock and/or leg ensuring comparable
440 groups at baseline for this variable.

441

442 **Abbreviations**

443 ANCOVA: Analysis of covariance; BMI: Body mass index; CI: Confidence interval; GP: General
444 practitioner; IQR: Interquartile range; VHT: Vestfold Hospital Trust; LBP: Low back pain; MIC:
445 Minimal important change; NNT: Number Needed To Treat; ODI: Oswestry Disability Index;
446 RCT: Randomised controlled trial

447

448 **Declarations**

449 Ethics approval and consent to participate

450 The Regional Committee for Medical Research Ethics South-East Norway (2017/2547/REK
451 sør-øst) approved the pilot trial before it started. All participants gave written informed
452 consent before entering the study.

453

454 Consent for publication

455 Not applicable. Our manuscript does not contain any individual person's data in any form.

456

457 Availability of data and materials

458 The datasets used and/or analysed during the current study are available from the
459 corresponding author on reasonable request.

460

461 Competing interests

462 The authors declare that they have no competing interests"

463

464 Funding

465 This study was funded by internal resources at VHT. The funding body has played no role in

466 the design, manuscript draft or decision to submit for the publication.

467

468 Authors' contributions

469 SL and MG had the idea of the project. SL treated the patients in the GDS group and drafted

470 the article. MG wrote the protocol for clinicaltrials.gov, conducted the statistical analyses,

471 and wrote parts of the manuscript. GH contributed to conceptualization and design of the

472 study, including writing parts of the protocol. MZS contributed to the randomization and

473 calculation of sample size. All authors have discussed the results and revised this manuscript

474 critically for important intellectual content. All authors read and approved the final

475 manuscript.

476

477 Acknowledgement

478 The authors would like to thank the participating doctors at the orthopaedic and physical

479 medicine departments at Vestfold Hospital and Inge Ringheim, PdD, Kysthospitalet Stavern,

480 for referring patients to this study. We will thank Stine Slaatten for helping with practicalities

481 and administrative tasks (information, randomization, and follow-ups) in the project, and

482 Anita Klepaker Hansen, who approved to conduct the study at the head of the physiotherapy

483 department of VHT.

484

485 Author details

486 ^a Physiotherapy Department at Vestfold Hospital Trust (VHT), P.O.Box 2168, 3103 Tønsberg,
487 Norway, ^b Oslo Metropolitan University, Department of physiotherapy, P.O. Box 4 St. Olavs
488 plass, NO-0130 Oslo, Norway, ^c FORMI, Oslo University Hospital HF, Ulleval, Bygg 37b, P.O.
489 Box 4956, Nydalen, 0424, Oslo, Norway

490

491 References

- 492 1. Hartvigsen J, Hancock MJ, Kongsted A, Louw Q, Ferreira ML, Genevay S, et al. What low back pain
493 is and why we need to pay attention. *The Lancet*. 2018;391(10137):2356-67
- 494 2. Brinjikji W, Diehn FE, Jarvik JG, et al. MRI Findings of disc degeneration are more prevalent in
495 adults with low back pain than in asymptomatic controls: a systematic review and meta-analysis. *Am*
496 *J Neuroradio* 2015; **36**: 2394–99.
- 497
498 3. Gibson JNA and Waddell G. Surgery for degenerative lumbar spondylosis. *Cochrane Database Syst*
499 *Rev*. 2005 Oct 19;2005(4):CD001352. PMID: **16235281**. PMCID: PMC7028012
500 DOI: 10.1002/14651858.CD001352.pub3
- 501
502 4. Foster N, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: evidence,
503 challenges, and promising directions. *Lancet* 2018;21 [http://dx.doi.org/10.1016/S0140-](http://dx.doi.org/10.1016/S0140-6736(18)30725-6)
504 [6736\(18\)30725-6](http://dx.doi.org/10.1016/S0140-6736(18)30725-6)
- 505
506 5. Chou R, Baisden J, Carragee EJ, Resnick DK, Shaffer WO, Loeser JD. Surgery for low back pain: a
507 review of the evidence for an American Pain Society clinical practice guideline. *Spine* 2009; **34**:
508 1094–109.
- 509
510 6. Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical versus nonoperative treatment for lumbar
511 spinal stenosis four-year results of the Spine Patient Outcomes Research Trial. *Spine* 2010;**35**:
512 1329–38.
- 513
514 7. Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National clinical guidelines for non-surgical treatment
515 of patients with recent onset low back pain or lumbar radiculopathy. *Eur Spine J* 2018; **27**: 60–75.
516 *Ann Intern Med* 2017; **166**: 514–30.
- 517
518 8. UK National Institute for Health and Care Excellence. Low back pain and sciatica in over 16s:
519 assessment and management. November 2016.<https://www.nice.org.uk/guidance/ng59> (accessed
520 Nov 7, 2017).
- 521
522 9. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for
523 chronic low back pain. *Cochrane Database Syst Rev* 2014; **9**: CD000963.

524
525 10. Wong JJ, Cote P, Sutton DA, et al. Clinical practice guidelines for the noninvasive management of
526 low back pain: a systematic review by the Ontario Protocol for Traffic Injury Management (OPTIMA)
527 Collaboration. *Eur J Pain* 2017; **21**: 201–16.
528
529 11. Ferreira PH, Ferreira ML, Maher CG, et al. Specific stabilisation exercise for spinal and pelvic pain:
530 a systematic review. *Aust J Physiother.* 2006;52:79 – 88.
531
532 12. Macedo LG, Maher CG, Latimer J, et al. Motor control exercises for persistent nonspecific low
533 back pain: a systematic review. *Phys Ther.* 2009;89:9 –25.
534
535 13. Saragiotto BT Maher CG, Yamato TP, Costa LOP, Costa LCM, Ostelo RWJG, Macedo LG. Motor
536 control exercise for chronic non-specific low-back pain. *Cochrane Database Syst Rev.* 2016.
537 <https://doi.org/10.1002/14651858.CD012004>
538
539 14. Diaz Arribas, M.J., et al., Effectiveness of the physical therapy Godelive Denys-Struyf method for
540 nonspecific low back pain: primary care randomized control trial. *Spine (Phila Pa 1976)*, 2009. **34**(15):
541 p. 1529-38.
542
543 15. Diaz-Arribas, M.J., et al., Effectiveness of the Godelive Denys-Struyf (GDS) method in people
544 with low back pain: cluster randomized controlled trial. *Phys Ther*, 2015. **95**(3): p. 319-36.
545
546 16. Sandra M Eldridge, Claire L Chan, Michael J Campbell, Christine M Bond, Sally Hopewell,
547 Lehana Thabane, Gillian A Lancaster, the PAFS consensus group. CONSORT 2010 statement:
548 extension to randomised pilot and feasibility trials. *BMJ* 2016;355:i5239 | doi: 10.1136/bmj.i5239
549
550 17. Hill JC, Dunn KM, Lewis M, Mullis R, Main CJ, Foster NE. A primary care back pain screening tool:
551 identifying patient subgroups for initial treatment. *Arthritis Rheum.* 2008;59(5):632-641.
552
553 18. Fairbank JC, Couper J, Davies JB, O'Brien JP (1980) The Oswestry low back pain disability
554 questionnaire. *Physiotherapy* 66:271–273. doi: PMID: 6450426.
555
556 19. Grotle et al 14. Grotle M, Brox JI, Vøllestad NK. Concurrent comparison of responsiveness in pain
557 and functional status measurements used for patients with low back pain. *Spine.* 2005;29:E492–
558 E501. doi: 10.1097/01.brs.0000143664.02702.0b.
559
560 20. McCormack, H.M., D.J. Horne, and S. Sheather, Clinical applications of visual analogue scales: a
561 critical review. *Psychol Med*, 1988. **18**(4): p. 1007-19.
562
563 21. EQ – 5D-5L-Norsk. Spørreskjema om helse. Norsk versjon, for Norge (Norwegian version for
564 Norway). [cited 2017 24.11.2017]; Available from: [cpup.se/wp-](http://cpup.se/wp-content/uploads/2017/01/Norwegian-EQ-5D-5L-Norsk.docx)
565 [content/uploads/2017/01/Norwegian-EQ-5D-5L-Norsk.docx](http://cpup.se/wp-content/uploads/2017/01/Norwegian-EQ-5D-5L-Norsk.docx).
566
567 22. Austevoll IM, Gjestad R, Grotle M, Solberg T, Brox JI, Hermansen E, Rekeland F, Indrekvam K,
568 Storheim K, Hellum C. Follow-up score, change score or percentage change score for determining
569 clinical important outcome following surgery? An observational study from the Norwegian registry
570 for Spine surgery evaluating patient reported outcome measures in lumbar spinal stenosis and
571 lumbar degenerative spondylolisthesis. *BMC Musculoskelet Disord.* 2019 Jan 18;20(1):31. doi:
572 10.1186/s12891-018-2386-y. PMID: 30658613
573

- 574 23. Werner DAT, Grotle M, Gulati S, Austevoll IM, Madsbu MA, Lønne G, Solberg TK. Can a Successful
575 Outcome After Surgery for Lumbar Disc Herniation Be Defined by the Oswestry Disability Index Raw
576 Score? *Global Spine J.* 2020 Feb;10(1):47-54. doi: 10.1177/2192568219851480. Epub 2019 Jun 6.
577 PMID: 32002349
578
- 579 24. R. Froud, S. Eldridge, R.Lall, M.Underwood, Estimating NNT from continuous outcomes in
580 randomised controlled trials: Methodological challenges and worked example using data from the UK
581 Back Pain Exercise and Manipulation. (BEAM) trial ISRCTN32683578. *BMC Health Services Research*
582 2009.
- 583 25. R. Bender, Calculating confidence intervals for the Number Needed to Treat Controlled clinical
584 trials 22-102-110, 2001.
- 585 26. Kongsted A, Kent P, Jensen TS, Albert H, Manniche C. Prognostic implications of the Quebec Task
586 Force classification of back-related leg pain: an analysis of longitudinal routine clinical data. *BMC*
587 *Musculoskelet Dis* 2013; **14**: 171.
588
- 589 27. Hellum C, Johnsen LG, Storheim K, Nygaard ØP, Brox JI, Rossvoll I, Rø M, Sandvik L, Grundnes O,
590 and the Norwegian Spine Study Group. Surgerywith disc prosthesis versus rehabilitation in patients
591 with lowbackpain and degenerative disc: two yearfollow-up of randomised study. *BMJ*
592 2011;342:d2786 doi:10.1136/bmj.d2786

Figures




Figure 1

Participants flow through the pilot study.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [TABLESPilotandfeasibilityjournal070422.pdf](#)
- [Consortextendedchecklist070422L003253.pdf](#)